港股異動 | 四環醫藥(0460.HK)漲約4% 中期純利勁升258.6% 醫美業務貢獻浮現
格隆匯8月31日丨四環醫藥(0460.HK)漲近4%,報2.21港元,總市值209億港元。四環醫藥公佈截至2021年6月30日止6個月的中期業績,期內集團實現來自持續經營業務收益19.07億元人民幣,同比增長80.9%;增加主要新業務醫美業務板塊帶動。今年2月後,公司開始銷售於韓國連續5年銷售第一的肉毒毒素產品樂提葆。期內,醫美業務板塊錄得收益2.6億元。毛利14.67億元,同比增長86.6%,毛利率由上年同期的74.5%的增至76.9%;經營溢利8.86億元,同比增長181.1%;公司擁有人應占溢利6.11億元,同比增長258.6%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.